<DOC>
	<DOCNO>NCT02168920</DOCNO>
	<brief_summary>To evaluate efficacy ( base mean change Cohen-Mansfield Agitation Inventory [ CMAI ] total score baseline primary efficacy variable ) , dose-response , safety aripiprazole 2 , 3 , 6 mg/day comparison placebo patient agitation associate Alzheimer 's type dementia</brief_summary>
	<brief_title>Aripiprazole Treatment Patients With Agitation Associated With Dementia Alzheimer 's Type</brief_title>
	<detailed_description>This trial multicenter , randomize , double-blind , placebo-controlled , parallel-group , comparison trial ass efficacy safety aripiprazole patient agitation associate Alzheimer 's type dementia . Screening period 4 week . Patients randomly assign one 4 group , treatment period 10 week . Period post-treatment observation 30 day .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Patients whose legal representative provide inform consent ( Informed consent patient possible ) . Patients satisfy follow diagnostic criterion : Diagnosis major neurocognitive disorder due Alzheimer 's disease accord Diagnostic Statistical Manual mental disorder ( DSM5 ) Diagnosis probable Alzheimer 's disease accord National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) Hospitalized patient care facility patient Patients MiniMental State Examination ( MMSE ) score 1 22 Patients complication dementia memory impairment Alzheimer 's type dementia Dementia patient Modified Hachinski Ischemic Score 5 high Patients psychological symptom behavioral disorder clearly due medical condition substance Patients complication history stroke transient ischemic attack , except asymptomatic stroke Patients heart failure classify New York Heart Asscoiation ( NYHAï¼‰ III IV Patients require drug therapy arrhythmia ischemic heart disease Body weight less 30 kg Patients high risk suicide Patients complication history seizure disorder Patients complication history neuroleptic malignant syndrome , tardive dyskinesia , paralytic ileus , rhabdomyolysis Patients thyroid disease ( except disease stabilize drug therapy 3 month longer prior time informed consent )</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Alzeheimer</keyword>
</DOC>